JP Morgan Chase
LXEO icon

JP Morgan Chase’s Lexeo Therapeutics LXEO Stock Holding History

JP Morgan Chase’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$491K Buy
93,163
+63,302
+212% +$449K ﹤0.01% 5046
2025
Q4 		$297K Buy
29,861
+15,502
+108% +$141K ﹤0.01% 5321
2025
Q3 		$95.3K Buy
14,359
+609
+4% +$2.94K ﹤0.01% 5930
2025
Q2 		$55.3K Sell
13,750
-30
-0.2% -$99 ﹤0.01% 5888
2025
Q1 		$47.8K Buy
13,780
+409
+3% +$1.81K ﹤0.01% 5898
2024
Q4 		$88K Buy
13,371
+3,093
+30% +$24.4K ﹤0.01% 5802
2024
Q3 		$92.9K Buy
10,278
+5,915
+136% +$70.5K ﹤0.01% 5734
2024
Q2 		$70K Sell
4,363
-1,590
-27% -$23.1K ﹤0.01% 5708
2024
Q1 		$93.3K Buy
5,953
+5,841
+5,215% +$91.3K ﹤0.01% 5702
2023
Q4 		$1.5K Buy
+112
New +$1.39K ﹤0.01% 6769

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return